

Application No.: 09/822,965

2

Docket No.: 220002059710

AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims

1-13. (canceled)

14. (previously presented): An isolated apo-B100 protein comprising a proteoglycan receptor⁺ mutation in Site B, wherein Site B is equivalent to amino acids from about 3358 to about 3369 of the human apo-B100 protein and wherein the mutation comprises at least one amino acid substitution or deletion of at least one of Lys₃₃₆₃ or Arg₃₃₆₂.

15-17. (canceled)

18. (previously presented): The apo-B100 protein according to claim 14, wherein said mutation in Site B is at position 3363 and the lysine residue is replaced with a glutamic acid residue, and the amino acid sequence from position 3358 to 3367 is:

Thr₃₃₅₈-Arg₃₃₅₉-Leu₃₃₆₀-Thr₃₃₆₁-Arg₃₃₆₂-Glu₃₃₆₃-Arg₃₃₆₄-Gly₃₃₆₅-Leu₃₃₆₆-Lys₃₃₆₇ (SEQ ID NO:1).

19. (currently amended): A polypeptide comprising the amino acid sequence of a proteoglycan receptor⁺ mutation in Site B of [[in the]] apo-B100 protein according to claim 14, wherein said Site B is equivalent to amino acids from 3358 to 3379, from 3348 to 3369, or from 3348 to 3379 of the flanked on at least one side by a contiguous sequence of at least 10 amino acids which is directly adjacent to Site B in the wild-type human apo-B100 sequence protein, wherein the mutation comprises at least one amino acid substitution or deletion of at least one of Lys₃₃₆₃ or Arg₃₃₆₂.

sd-228535

Application No.: 09/822,965

3

Docket No.: 220002059710

20. (previously presented): An LDL particle comprising an apo-B100 protein according to claim 14.

21-28. (canceled)

sd-228535